Testing a new therapy for metastatic cancer
Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer
This study is testing a new treatment called MN-anti-miR10b that aims to help people with metastatic cancer by targeting and eliminating cancer cells, and it may be used alongside low-dose chemotherapy to help shrink tumors.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Transcode Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11005913 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic agent designed to specifically target and eliminate metastatic cancer cells. The therapy, known as MN-anti-miR10b, utilizes a unique delivery system to inhibit a specific microRNA associated with cancer spread. Patients may receive this treatment in combination with low-dose chemotherapy, with the aim of achieving significant regression of metastases. The approach has shown promising results in preclinical models, suggesting potential effectiveness in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage cancer or those whose cancer has not metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly reduces or eliminates metastatic cancer, improving survival rates for patients.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting microRNAs in cancer therapy, indicating potential for success in this novel treatment.
Where this research is happening
Boston, United States
- Transcode Therapeutics, INC. — Boston, United States (Active)
Researchers
- Principal investigator: Medarova, Zdravka O — Transcode Therapeutics, INC.
- Study coordinator: Medarova, Zdravka O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.